Reactivation of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation

Leukemia and Lymphoma

Volumn 39, Issue 3-4, 2000, Pages 229-239

  Maeda, Y ^a   Teshima, T ^a   Yamada, M ^a   Harada, M ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

BMT; Engraftment; Human herpesvirus; Latency; PBSCT; Reactivation

Indexed keywords

CD4 ANTIGEN; VIRUS ANTIGEN; VIRUS DNA;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; BODY FLUID; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE SEVERITY; EPSTEIN BARR VIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS; HERPES VIRUS INFECTION; HOST; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; HUMORAL IMMUNITY; IMMUNOASSAY; IMMUNOCOMPETENCE; INCIDENCE; LEUKOCYTE; MEDICAL LITERATURE; NONHUMAN; PATIENT MONITORING; PERIPHERAL BLOOD STEM CELL; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RECIPIENT; REVIEW; SYMPTOM; T LYMPHOCYTE SUBPOPULATION; THROMBOCYTE; VARICELLA ZOSTER VIRUS; VIREMIA; VIRUS DETECTION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS SHEDDING;

EID: 0034487546     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009065823     Document Type: Review

References (100)

1. Reimmunization after blood or marrow stem cell transplantation
2. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation
3. Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation
4. The kinetics of immune reconstitution after human marrow transplantation
5. Recovery of antibody production in human allogeneic marrow graft recipients: Influence of time postransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment
6. The graft-versus-host reaction and immune function. I. T helper cell immunodeficiency associated with graft-versus-host-induced thymic epithelial cell damage
7. Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation
8. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow
9. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow
10. Cytomegalovirus infection after bone marrow transplantation: An association with acute graft-v-host disease
11. The latent herpes simplex virus type 1, genome copy number in individual neurons is virus strain specific and correlates with reactivation
12. Virologic characteristics of subclinical and symptomatic genital herpes infections
13. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment
14. Viral infections in neutropenia-current problems and chemotherapeutic control
15. Acyclovir prophylaxis of herpes-simplex-virus infections
16. Antimicrobial prophylaxis in bone marrow transplantation
17. Viral infections in leukemia and bone marrow transplant patients
18. Immune reconstitution and viral infections after stem cell transplantation
19. Effect of B cell suppression on primary infection and reinfection of mice with herpes simplex virus
20. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes
21. Evolution of recurrent herpes simplex lesions. An immunohistologic study
22. Primary and secondary syphilis lesions contain mRNA for Th1 cytokines
23. Cellular responses to interferon-gamma
24. Herpes simplex virus infection of human fibroblasts and keratinocytes inhibits recognition by cloned CD8+ cytotoxic T lymphocytes
25. Tipping the scales of herpes simplex virus reactivation: The important responses are local
26. Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia
27. Human herpes viruses latent infection in the nervous system
28. Varicella zoster virus infections following allogeneic bone marrow transplantation: Frequency, risk factors, and clinical outcome
29. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation
30. Cell-mediated immunity to varicella-zoster virus after allogeneic marrow transplant
31. Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype
32. Epstein-Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen
33. Antibody-dependent lymphocyte cytotoxicity against cells expressing Epstein-Barr virus antigens
34. Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate
35. Analysis of the defects responsible for the impaired regulation of Epstein-Barr virus-induced B cell proliferation by rheumatoid arthritis lymphocytes. I. Diminished gamma interferon production in response to autologous stimulation
36. Immunoregulatory abnormalities in patients with Epstein-Barr virus-associated B cell lymphoproliferative disorders
37. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
38. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation
39. Semiquantitative Epstein-Barr virus polymerase chain reaction analysis of peripheral blood from organ transplant patients and risk for the development of lymphoproliferative disease
40. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease
41. Malignancies after hematopoietic stem cell transplantation: Many questions, some answers
42. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts
43. Adoptive cellular immunotherapy for EBV lymphoproliferative disease
44. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: Risk factors, treatment and outcome
45. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation
46. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
47. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
48. Risk factors for cytomegalovirus infection after human marrow transplantation
49. Nonbacterial pneumonia after allogeneic marrow transplantation: A review of ten years' experience
50. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants
51. Progress in the treatment of cytomegalovirus pneumonia
52. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin
53. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients
54. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years
55. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group
56. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors
57. Transmission and activation of cytomegalovirus with blood transfusion: A mouse model
58. Replication of human cytomegalovirus in human peripheral blood T cells
59. Wolf in wolf's clothing: Is it time to raise the bounty on the passenger leukocyte?
60. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: Importance of cytomegalovirus viremia
61. Direct detection of cytomegalovirus in peripheral blood leukocytes--a review of the antigenemia assay and polymerase chain reaction
62. Quantitation of cytomegalovirus: Methodologic aspects and clinical applications
63. Molecular biology and immunology of cytomegalovirus
64. Specific cell-mediated immunity and the natural history of congenital infection with cytomegalovirus
65. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients
66. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones
67. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease
68. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
69. Identification of human herpesvirus-6 as a casual agent for exanthem subitum
70. Bone marrow transplant recipients harbor the B variant of human herpesvirus 6
71. Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation
72. Reactivation of herpesvirus type 6 in children receiving bone marrow transplants for leukemia
73. Interstitial pneumonitis associated with human herpesvirus-6 infection after marrow transplantation
74. Brief report: Fatal encephalitis due to variant B human herpesvirus-6 infection in a bone marrow-transplant recipient
75. Human herpesvirus 6 infections after bone marrow transplantation: Clinical and virologic manifestations
76. Human herpesvirus 6 (HHV-6) isolation from bone marrow: HHV-6 associated bone marrow suppression in bone marrow transplant patients
77. Human herpesvirus-6 (HHV-6) infection in allogeneic bone marrow transplant recipients: Evidence of a marrow-suppressive role for HHV-6 in vivo
78. Disseminated human herpesvirus 6 infection in AIDS
79. HHV-6 and CMV pneumonitis in immunocompromised patients
80. Specificity analysis of human CD4+ T-cell clones directed against human herpesvirus 6 (HHV-6), HHV-7, and human cytomegalovirus
81. Lymphotropic herpesviruses in allogeneic bone marrow transplantation
82. Suppressive effects of human herpesvirus 6 on in vitro colony formation of hematopoietic progenitor cells
83. Suppressive effects of human herpesvirus-6 on thrombopoietin-inducible megakaryocytic colony formation in vitro
84. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma
85. KSHV and Kaposi's sarcoma: The end of the beginning?
86. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS- related body-cavity-based lymphomas
87. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients
88. Risk of Kaposi's sarcoma-associated herpes virus transmission from donor allografts among Italian postransplant Kaposi's sarcoma patients
89. Human herpesvirus 8 and renal transplantation
90. Kaposi's sarcoma after allogeneic bone marrow transplantation
91. Human herpes virus 8 (HHV8) serology in allogeneic bone marrow transplant recipients
92. Improved reconstitution of CD4 T cells and B cells but worsened reconstitution of serum IgG levels after allogeneic transplantation of blood stem cells instead of marrow
93. Differential contribution of thymic outputs and peripheral expansion in the development of peripheral T cell pools
94. Peripheral selection of T cell repertoires: The role of continuous thymus output
95. The role of the thymus and recent thymic migrants in the maintenance of the adult peripheral lymphocyte pool
96. Pathways of T-cell regeneration in mice and humans: Implications for bone marrow transplantation and immunotherapy
97. Immune reconstitution following allogeneic peripheral blood stem cell transplants
98. Analysis of late infections in 89 long-term survivors of bone marrow transplantation
99. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts
100. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease